Lilly has been solidly investing in research and development (R&D) throughout 2024. In April, the company announced the ...

Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.

The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by up to 50%, a study found, adding to mounting evidence ...

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

Britain will study whether the use of Eli Lilly’s weight loss drug can get people back into work and help tackle the high ...

Drastic action is considered essential, but this is part of a wider strategy that represents a looming calamity for Stormont ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

"These are not case-specific issues," the plaintiffs contended. "The marketing was national in scale and magnitude, and ...

Severe malnutrition is treated with ready-to-use therapeutic food, a paste combining peanuts, sugar, milk powder, oil, ...

It is primary aim is to analyse how tirzepatide, sold by Eli Lilly under the brand name Mounjaro, reduces obesity and other ...